Repros Therapeutics Inc. (RPRX Quick QuoteRPRX - Free Report) reported a loss of 18 cents per share in the second quarter of 2016, significantly narrower than the year-ago loss of 32 cents mainly due to lower research & development (R&D) expenses as well as lower payroll and benefits expenses and legal expenses. Second-quarter revenues (interest income) increased to $15,000 from $1,000 in the year-ago period.

R&D costs decreased 49.7% year over year to $3.2 million reflecting lower development expenses related to the enclomiphene product candidate, R&D payroll and benefits expenses and legal expenses. General and administrative expenses also decreased 22% year over year to $1.1 million.

Considering that Repros has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.

Repros is currently working on gaining EU approval for enclomiphene (testosterone deficiency), where the company expects to submit a marketing application in Fall 2016. Meanwhile, in the U.S., a phase II double-blind, placebo controlled, proof of concept study (ZA-205) is being conducted in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. Six month data from this study is expected in the third quarter of 2016.

The company’s other pipeline candidate, Proellex, is in mid-stage development for the treatment of symptoms associated with uterine fibroids and endometriosis.

REPROS THERAPEU Price

REPROS THERAPEU Price | REPROS THERAPEU Quote

Repros is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector are Geron Corporation (GERN Quick QuoteGERN - Free Report) ), Incyte Corporation (INCY Quick QuoteINCY - Free Report) and Cambrex Corporation . All three carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>